CORCEPT THERAPEUTICS INC

CORT

Form 4 • Statement of Changes in Beneficial Ownership

SEC Accession Number: 0001193125-26-092157
Filing date: Mar 4, 2026
Earliest execution date: Mar 2, 2026

Summary

Type

Neutral

Net shares

+996

% of shares

80.65%

Amount (USD)

$0

Insider confidence score

90.0 out of 100

Positive

  • Massive buy (≥10% of shares)

Negative

  • Minimal buy amount (<$10K)

Stock transactions

Transaction 1

Security

Common Stock

Action

Grant

Date

2026-03-02

Code

A

Net shares

+498.0

Price per Share

$35.97

Amount (USD)

$17,913.06

Acquired/Disposed

Acquired

Shares Owned Before

1,235.0

Shares Owned After

1,733.0

Transaction 2

Security

Common Stock

Action

Grant

Date

2026-03-02

Code

A

Net shares

+498.0

Acquired/Disposed

Acquired

Shares Owned Before

1,733.0

Shares Owned After

2,231.0

Filing's footnotes

1. The Reporting Person purchased shares (&quot;Purchase Plan Shares&quot;) of the Issuer's common stock pursuant to a purchase plan (&quot;Purchase Plan&quot;) established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on March 2, 2026.

2. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

3. Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

4. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

This page is for informational purposes only. While we strive for accuracy, the summary may contain inaccuracies or omissions. Please refer to the official SEC filing for authoritative information. Open the SEC filing.